NeuroSense Therapeutics Ltd. (NRSN)
| Market Cap | 26.85M +8.7% |
| Revenue (ttm) | n/a |
| Net Income | -11.13M |
| EPS | -0.44 |
| Shares Out | 35.35M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 149,358 |
| Open | 0.7800 |
| Previous Close | 0.7703 |
| Day's Range | 0.7500 - 0.8400 |
| 52-Week Range | 0.6300 - 2.6000 |
| Beta | 1.58 |
| Analysts | Strong Buy |
| Price Target | 8.38 (+1,003.21%) |
| Earnings Date | Mar 31, 2026 |
About NRSN
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical stu... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for NRSN stock is "Strong Buy." The 12-month stock price target is $8.38, which is an increase of 1,003.21% from the latest price.
News
NeuroSense Therapeutics Slides: Corporate presentation
NeuroSense Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 4, 2026.
NeuroSense Announces Pricing of Insider-Led PIPE Financing
Financing led by CEO Alon Ben-Noon and CFO Or Eisenberg, alongside participation from an existing significant shareholder CAMBRIDGE, Mass., April 28, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense announces departure of Chief Medical Officer
NeuroSense (NRSN) announced on Friday that Dr. Ferenc Tracik will step down from his role as the company’s Chief Medical Officer, effective April 27. Tracik will continue to support the…
NeuroSense Therapeutics Slides: Corporate presentation
NeuroSense Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on April 14, 2026.
NeuroSense granted Brazilian patent covering PrimeC composition
NeuroSense (NRSN) Therapeutics announced that the Brazilian Patent and Trademark Office has granted Brazilian Patent No. BR 112024007727-6, entitled “Compositions Comprising Ciprofloxacin and Celecoxi...
NeuroSense Granted Brazilian Patent Covering PrimeC Composition
Patent Protection Through October 2042 Follows prior patent grants in the U.S. and Australia Further strengthens NeuroSense's global intellectual property portfolio CAMBRIDGE, Mass., April 6, 2026 /PR...
NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements
Notifications have no immediate effect on the listing or trading of the Company's securities on Nasdaq Nasdaq has provided the Company until September 29, 2026 to regain compliance with both requireme...
NeuroSense Therapeutics Annual report: Q4 2025
NeuroSense Therapeutics has published its Q4 2025 annual report on March 31, 2026.
NeuroSense Therapeutics Earnings release: Q4 2025
NeuroSense Therapeutics released its Q4 2025 earnings on March 31, 2026, summarizing the period's financial results.
NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update
2025 marked transition of PrimeC into a late-stage clinical asset with FDA-cleared Phase 3 program in ALS Statistically significant survival benefit demonstrated, including 65% reduction in risk of de...
NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout
CAMBRIDGE, Mass., March 24, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
PrimeC New Data to Be Presented at AD/PD™ 2026 Conference
Dr. Christian Lunetta to Present "From PARADIGM to PARAGON: Advancing PrimeC for ALS through Phase 2 Clinical and Biomarker Insights toward a Global Phase 3 Trial" CAMBRIDGE, Mass., March 18, 2026 /PR...
JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity
The Journal of the American Medical Association (JAMA Neurology) publication highlights consistent clinical and biomarker findings from NeuroSense PARADIGM Phase 2b trial in ALS, including slower func...
NeuroSense Therapeutics Slides: Corporate presentation
NeuroSense Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on March 11, 2026.
NeuroSense initiated with a Buy at Roth Capital
Roth Capital analyst Boobalan Pachaiyappan initiated coverage of NeuroSense (NRSN) with a Buy rating and $3 price target The firm is positive on PrimeC’s ability to reduce disability and improve…
PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference
CAMBRIDGE, Mass., March 9, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense reports additional long-term survival data from PARADIGM 2b trial
NeuroSense (NRSN) Therapeutics announced the availability of additional long-term survival data from its previously completed PARADIGM Phase 2b clinical trial evaluating PrimeC in patients with amyotr...
NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS
CAMBRIDGE, Mass., Feb. 18, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense granted Australian patent covering PrimeC composition
NeuroSense (NRSN) Therapeutics announced that the Australian Patent Office has granted Australian Patent No. 2022370513, entitled “Compositions Comprising Ciprofloxacin and Celecoxib,” representing an...
NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition
Strengthens Global IP Portfolio for PrimeC Through 2042 CAMBRIDGE, Mass., Feb. 9, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense files $150M mixed securities shelf
17:29 EST NeuroSense (NRSN) files $150M mixed securities shelf
NeuroSense Therapeutics Registration statement: Registration Filing
NeuroSense Therapeutics filed a registration statement on January 29, 2026, providing details about a securities offering with the SEC.
NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease
Patent protection extended through 2043 Alzheimer's proof-of-concept study completed Clinical and Biomarker Outcomes Expected in Q1 2026 CAMBRIDGE, Mass., Jan. 21, 2026 /PRNewswire/ -- NeuroSense Ther...
World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB
Alzheimer's Clinical and Biomarker Outcomes Expected in Q1 2026 CAMBRIDGE, Mass., Jan. 8, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Slides: Corporate presentation
NeuroSense Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on January 4, 2026.